-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Table 1 Bispecific antibody platform
Table 2 Approved clinical status of domestic double antibodies
Data source: Yaozhi data
From the perspective of research and development progress, there are many products in the early clinical stage.
Kangfang Bio's AK104 and Kangning Jerry's KN046 are progressing quickly and have entered the third clinical phase
.
In terms of the number of research and development, Cinda Bio has 7 bispecific antibodies that have entered the clinic, and BeiGene and Baili Pharmaceutical have also entered the clinical stage of a large number of bi-antibody drugs
.
summary
Multispecific drugs are an important part of innovative drug discovery and the future development trend.
In addition to double antibodies, polyclonal products also have products in the research stage
.
It should be noted that the clinical value of drug development is the core
.
On July 2, 2021, the Food and Drug Administration issued the "Clinical Value-Oriented Anti-tumor Drug Clinical R&D Guidelines" for soliciting comments, stating that "the research and development of new drugs should provide patients with better treatment options as the highest goal.
" The unmet clinical needs are the key
.
Multispecific drugs have many advantages in theory, but whether they can be transformed into clinical advantages requires more scientific research to prove
.
Reference materials:
Antibody Therapeutics, 2020, Vol.
3, No.
1 18–62.
doi:10.
1093/abt/tbaa003.
Editor in charge: Liuli
